MedTrace Logo

VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs

NCT04242706 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 323

Last updated 2021-01-20

No results posted yet for this study

Summary

The study objective is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard coating. The study is randomized, prospective, controlled and blinded. All adult patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study.

Conditions

  • Ventilator-associated Pneumonia

Interventions

DEVICE

ETTEvac

Endotracheal tube with evacuation lumen without noble metal coating

DEVICE

BIP ETTEvac

Endotracheal tube with evacuation lumen with noble metal coating

Sponsors & Collaborators

  • Bactiguard AB

    lead INDUSTRY

Principal Investigators

  • Benoit Misset, MD,Prof. · CHU, Liege; Belgium

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2020-05-08
Completion
2020-05-08

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04242706 on ClinicalTrials.gov